Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02570490 · ClinicalTrials.gov registry record · Phase 3
Oral Sodium Fusidate (CEM-102) Versus Oral Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections
A Phase 3 study of Acute Bacterial Skin and Skin Structure Infections, sponsored by Arrevus.
- Completed
- Registry status
- Phase 3
- Development phase
- 716
- Enrollment target
- 20
- Study locations
NCT02570490: Completed Phase 3 study of Acute Bacterial Skin and Skin Structure Infections, sponsored by Arrevus.
NCT02570490 is a Phase 3 study of Acute Bacterial Skin and Skin Structure Infections that has completed, run by Arrevus. The registered enrollment target is 716 participants. The trial reports 20 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02570490, a Phase 3 study of Acute Bacterial Skin and Skin Structure Infections, has completed, sponsored by Arrevus.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 716 participants
- Enrollment target
- 20
- Study locations
Study Summary
Phase 3, randomized, double-blind, multi-center efficacy and safety study to evaluate an oral CEM-102 loading dose regimen compared to oral linezolid in the treatment of subjects with ABSSSI
Conditions Studied
Interventions
- DRUG linezolid
- DRUG sodium fusidate
Study Locations (20)
California
- - Anaheim
- - Bakersfield
- - Buena Park
- - Fountain Valley
- - La Mesa
- - La Palma
- - Long Beach
- - Los Angeles
- - Modesto
- - National City
- - Oceanside
- - Riverside
- - San Diego
- - San Diego
- - San Diego
- - San Diego
- - San Diego
- - San Dimas
- - Stockton
- - Sylmar
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 716 participants |
| Start Date | 2015-11 |
| Est. Completion | 2016-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02570490
The ClinicalTrials.gov registry entry for NCT02570490 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 716 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Arrevus, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Acute Bacterial Skin and Skin Structure Infections appearing as the primary indexed condition, and to 2 interventions - of which linezolid is the first listed.
NCT02570490 reports 20 study locations spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT02570490 about?
NCT02570490 is a clinical study titled "Oral Sodium Fusidate (CEM-102) Versus Oral Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections". Phase 3, randomized, double-blind, multi-center efficacy and safety study to evaluate an oral CEM-102 loading dose regimen compared to oral linezolid in the treatment of subjects with ABSSSI
What is the current status of trial NCT02570490?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 716 participants. The study started on 2015-11. Estimated completion is 2016-11.
What conditions does trial NCT02570490 study?
This clinical trial studies the following conditions: Acute Bacterial Skin and Skin Structure Infections.
What interventions are being tested in trial NCT02570490?
The interventions under investigation include: linezolid (DRUG), sodium fusidate (DRUG).
Who is sponsoring clinical trial NCT02570490?
This trial is sponsored by Arrevus, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02570490 being conducted?
This trial has 20 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Bacterial Skin and Skin Structure Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.